Bausch & Lomb Corp (BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Ticker
BLCO
Exchange
NYSE
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$7.14B
52-week range
$14.44 - $21.36

Valuation

Share price
$19.99 (close of Nov 6, 2026)
P/E (TTM)
-64.48x
Price to book
1.10x
Price to free cash flow
28.35x
Enterprise value
$11.73B
Book value per share
$18.22

Price performance

PeriodChange
1 day+0.35%
5 days-0.05%
1 month+16.36%
3 months+22.26%
6 months+24.94%
Year to date+17.04%
1 year+28.72%
3 years+20.35%
All time-0.05%

Short interest

As of
Oct 15, 2026
Short % of float
5.48%
Shares short
2.54M
Days to cover
3.60
Change since prior report
-14.05%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-5.52%
Return on invested capital
0.67%
Return on assets
-2.57%
Return on capital employed
0.93%
Gross margin
53.28%
Net margin
-7.06%
EBITDA margin
10.47%
Revenue growth
6.47%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.53%
Current ratio
1.56x
Net debt to EBITDA
5.85x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$5.10B
Cost of revenue
$2.38B
Gross profit
$2.72B
EBITDA
$534.00M
Net income
-$360.00M
Earnings per share
$-1.02
Research and development
$371.00M
Shares outstanding
353.80M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$5.10B$2.72B-$360.00M-$1.02
2024-12-31$4.79B$2.59B-$317.00M-$0.90
2023-12-31$4.15B$2.19B-$260.00M-$0.74
2022-12-31$3.77B$1.99B$6.00M$0.02
2021-12-31$3.77B$1.99B$182.00M$0.52
2020-12-31$3.41B$1.77B-$18.00M-$0.05
2019-12-31$3.78B-$298.00M$0.85
2018-12-31$3.67B-$710.00M$2.03

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3153.28%-7.06%-5.52%0.67%
2024-12-3154.00%-6.62%-4.84%0.80%
2023-12-3152.82%-6.27%-3.76%0.57%
2022-12-3152.87%0.16%0.08%1.56%
2021-12-3152.83%4.83%1.94%2.14%
2020-12-3151.76%-0.53%-0.18%-
2019-12-31-7.89%2.97%-
2018-12-31-19.37%--

Cash and debt by year

Period endCashDebt
2025-12-31$383.00M$5.02B
2024-12-31$305.00M$4.74B
2023-12-31$331.00M$4.53B
2022-12-31$354.00M$2.41B
2021-12-31$174.00M-

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$66.00M$149.00M
2024-12-31-$59.00M$92.00M
2023-12-31-$198.00M$74.00M
2022-12-31$170.00M$62.00M
2021-12-31$680.00M$62.00M
2020-12-31$269.00M$50.00M
2019-12-31$619.00M$50.00M
2018-12-31$662.00M$43.00M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-28Sep 2026$0.21
2026-07-29Jun 2026$0.16
2026-04-29Mar 2026$0.06
2026-02-18Dec 2025$0.35
2025-10-29Sep 2025$0.16
2025-07-30Jun 2025$0.06
2025-05-29--
2025-04-30Mar 2025$0.03

Filings and sources

Company website
bausch.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · Medline Inc. (MDLN) · ResMed Inc (RMD) · Alcon Inc (ALC) · West Pharmaceutical Services Inc (WST) · Solventum Corp (SOLV) · Baxter International Inc (BAX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades